Patents Examined by Dameron Levest Jones
  • Patent number: 9212385
    Abstract: The invention provides novel fluorinated resorufin compounds that are of use in a variety of assay formats. Also provided are methods of using the compounds and kits that include a compound of the invention and instructions detailing the use of the compound in one or more assay formats.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: December 15, 2015
    Assignee: Life Technologies Corporation
    Inventors: Robert H. Batchelor, Yue Ge, Iain Johnson, Wai-Yee Leung, Jixiang Liu, Brian Patch, Peter Smalley, Thomas Steinberg, Kyle Gee
  • Patent number: 9011816
    Abstract: Example systems and methods enhance contrast in MRI images. To facilitate imaging of atherosclerotic plaques, arterial and venous, cardiac, and even tumor tissues and fibrosis, a fibrin-fibronectin complex or disease-related fibronectin specific MRI contrast agent (CLPD) has a specific binding affinity for fibronectin.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: April 21, 2015
    Assignee: Case Western Reserve University
    Inventors: Zheng-Rong Lu, Xueming Wu
  • Patent number: 8920777
    Abstract: The invention provides an insulin-like growth factor-1 (IGF-1) receptor ligand carrying a therapeutic radionuclide for treatment of cancer is provided. A method of treating cancer using the IGF-1 receptor ligand carrying a therapeutic radionuclide is also provided. An anti-cancer therapeutic agent containing an IGF-1 receptor ligand linked to a toxin is also provided, as are methods of using the toxin conjugates for treatment of cancer.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: December 30, 2014
    Assignee: IGF Oncology, LLC
    Inventor: Hugh McTavish
  • Patent number: 8518374
    Abstract: There is provided a personal care product having a body side liner, a baffle and an indicator strip with two ends. The indicator has an amine sensitive dye near at least one end. The indicator extends from the target area just below the liner to just above the baffle such that the dye deposit is visible to an unaided eye. The dye changes color in the presence of amines which are characteristic of infection, thus alerting the user to the possibility of infection. Such an indicator placed in a feminine hygiene pad, for example, may be useful in the diagnosis of vaginits.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: August 27, 2013
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: RameshBabu Boga, John Gavin MacDonald
  • Patent number: 8287840
    Abstract: This invention is directed to methods of treating solid tumor cancers, particularly refractory cancers by administration of two pluralities of microparticles, one comprising drug-carrying microparticles sized to lodge at the tumor preferably in the capillary bed of the tumor and the other comprising non-drug-carrying microparticles sized to lodge in the arterial system servicing the tumor so as to embolize the tumor.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: October 16, 2012
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Liangxuan Zhang, Florencia Lim
  • Patent number: 8021646
    Abstract: The present application provides for compositions and methods of creating and applying contrast agents that find use in magnetic resonance imaging (MRI). In particular, contrast agents that comprise monodisperse, protein polymer backbones capable of chelating multiple paramagnetic ions resulting in high relaxivity for use in enhancing MRI signal intensity.
    Type: Grant
    Filed: December 7, 2007
    Date of Patent: September 20, 2011
    Assignee: Northwestern University
    Inventors: Lindsay K. Sulzer, Steven R. Bull, Annelise Emily Barron, Thomas J Meade
  • Patent number: 6852842
    Abstract: Small dendrimer-based MRI contrast agents are disclosed to accumulate in renal tubules. The accumulation enables visualization of renal structure and function, permitting assessment of structural and functional damage to the kidneys. In a disclosed embodiment, six, small dendrimer-based MRI contrast agents were synthesized, and their pharmacokinetics, whole body retention, and renal MRI images were evaluated in mice. Surprisingly, despite having unequal renal clearance properties, all of the dendrimer agents clearly visualized the renal anatomy and proximal straight tubules of the mice better than Gd-[DTPA]-dimeglumine. Dendrimer conjugate contrast agents prepared from PAMAM-G2D, DAB-G3D, and DAB-G2D dendrimers were excreted rapidly and may be acceptable for use in clinical applications.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: February 8, 2005
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Martin W. Brechbiel, Robert A. Star, Hisataka Kobayashi